Best-value biological medicines: Filgrastim
The Medicines Management Programme has identified best-value biological (BVB) medicines for medicinal products containing filgrastim on the High Tech Arrangement.
The MMP recommends the following as BVB medicines for filgrastim on the High Tech Arrangement:
- Accofil® (Accord Healthcare Ireland Limited)
- Tevagrastim® (Teva Pharmaceuticals Ireland).
A copy of the MMP Evaluation Report is available in the Related Files section below.
Clinicians should give due consideration to prescribing Accofil® or Tevagrastim® when issuing a prescription for filgrastim on the High Tech Arrangement. Prescribing the recommended BVB medicines reduces the financial burdens on the HSE arising out of the funding of reimbursed medicines, and can assist in facilitating access to new, innovative medicines for patients.
The MMP recommends that all new patients being initiated on treatment with filgrastim under the High Tech Arrangement should be prescribed one of the recommended BVB medicines.
Note: Please see the communication entitled MMP Communication - BVB Medicines Filgrastim 27 March 2025 in the Related Files section below for information on the availability of the BVB medicines during the initial stage of implementation of these recommendations.
Resources to support prescribing of the BVB medicines are located in the Related Files section below:
- MMP Communication - BVB Medicines Filgrastim 27 March 2025
- BVB Reimbursement of Filgrastim Questions and Answers for Healthcare Professionals April 2025
- BVB Filgrastim Patient Information April 2025